Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ovarian Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

118 recruiting trials for Ovarian Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 118 Ovarian Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 30% (21 studies); the largest phase groups are Phase 1: 21, Phase 2: 21, Phase 1 / Phase 2: 14, Phase 3: 8.

Research is led by AstraZeneca (3), National Cancer Institute (NCI) (3), A2 Biotherapeutics Inc. (2), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 9 trials), followed by pembrolizumab, Bevacizumab.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
118
Total Trials
118
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Track Ovarian Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 20016 locations
RECRUITINGPhase 1NCT07156253

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with...

Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdEnrolling: 1102 locations
RECRUITINGPhase 1 / Phase 2NCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or...

Sponsor: PMV Pharmaceuticals, IncEnrolling: 30020 locations
RECRUITINGPhase 1 / Phase 2NCT05123482

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Sponsor: AstraZenecaEnrolling: 46020 locations
RECRUITINGPhase 1NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or...

Sponsor: Dren BioEnrolling: 9610 locations
RECRUITINGNCT03787056

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric...

Sponsor: Hospices Civils de LyonEnrolling: 41017 locations
RECRUITINGPhase 1NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Sponsor: Clasp Therapeutics, Inc.Enrolling: 9020 locations
RECRUITINGPhase 1 / Phase 2NCT00722228

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her...

Sponsor: Hadassah Medical OrganizationEnrolling: 501 location
RECRUITINGPhase 1 / Phase 2NCT06799637

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor...

Sponsor: Evopoint Biosciences Inc.Enrolling: 35020 locations
RECRUITINGPhase 1NCT06910657

IDOV-Immune for Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not...

Sponsor: ViroMissile, Inc.Enrolling: 786 locations
RECRUITINGNCT05129969

Registry Platform Ovarian and Endometrial Cancer

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics,...

Sponsor: iOMEDICO AGEnrolling: 19751 location
RECRUITINGNCT05810701

FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer

Ovarian cancer (OC) is the fifth most common cause of cancer death. More than 40% are older than 70 years. The standard treatment is radical surgery combined with chemotherapy....

Sponsor: Odense University HospitalEnrolling: 3005 locations
RECRUITINGPhase 2NCT06180356

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery...

Sponsor: MedSIREnrolling: 3014 locations
RECRUITINGPhase 1NCT05039801

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 541 location
RECRUITINGPhase 1NCT06642363

The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with...

Abstract Background: This trial aims to investigate the effect of 12 weeks of 10 mg/day astaxanthin (ASX) administration compared with the control group on insulin sensitivity,...

Sponsor: Isfahan University of Medical SciencesEnrolling: 441 location
RECRUITINGNCT06331130

Mesenteric Infiltration in Ovarian Cancer

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 5101 location
RECRUITINGPhase 2NCT07171528

Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer

To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy

Sponsor: National Cancer Center, KoreaEnrolling: 801 location
RECRUITINGPhase 2NCT05231122

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With...

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that...

Sponsor: Roswell Park Cancer InstituteEnrolling: 802 locations
RECRUITINGNCT06665945

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression...

Sponsor: University of UtahEnrolling: 2451 location
RECRUITINGNCT06325956

PCOS Immune Function Predicts Metformin Efficacy

In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to...

Sponsor: Shanghai 10th People's HospitalEnrolling: 1001 location
RECRUITINGPhase 1NCT05103683

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

Sponsor: TORL Biotherapeutics, LLCEnrolling: 9014 locations
RECRUITINGPhase 1 / Phase 2NCT07523529

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker...

Sponsor: Beijing BiotechEnrolling: 721 location
RECRUITINGNCT05574673

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of...

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials UnitEnrolling: 10001 location
RECRUITINGEarly Phase 1NCT05080946

Using Aspirin to Improve Immunological Features of Ovarian Tumors

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 1004 locations
RECRUITINGNCT01102569

Pancreatic Cancer Genetics

The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly...

Sponsor: Columbia UniversityEnrolling: 1001 location
RECRUITINGNCT05912972

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer...

Sponsor: Asan Medical CenterEnrolling: 135001 location
RECRUITINGPhase 2 / Phase 3NCT06161025

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal,...

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Sponsor: Daiichi SankyoEnrolling: 86020 locations
RECRUITINGPhase 1NCT07310420

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2-...

The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).

Sponsor: TerSera Therapeutics LLCEnrolling: 8811 locations
RECRUITINGNCT07483723

Glucose Profiles in Women With Polycystic Ovary Syndrome

Polycystic ovary syndrome is a very common condition that is associated with metabolic complications. Patients with polycystic ovary syndrome exhibit insulin resistance and are at...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 801 location
RECRUITINGNCT06232213

Clinical Study of Individualized Treatment of Relapsed or Drug-resistant Advanced Gynecological Tumors Guided by PTC...

The clinical treatment of patients with resistant/relapsed/advanced gynecological malignancies is very difficult, and the difficulty lies in the selection of effective drugs. This...

Sponsor: Hua LiEnrolling: 401 location
RECRUITINGNCT07433660

WellSpan-THRIVE Cancer QOL Study

Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and...

Sponsor: WellSpan HealthEnrolling: 10005 locations
RECRUITINGNCT01558544

Cryopreservation of Ovarian Tissue

The study hopes to contribute to the development of technologies of ovarian tissue freezing-thawing and in vitro maturation of immature eggs such that a person at risk for...

Sponsor: Weill Medical College of Cornell UniversityEnrolling: 3001 location
RECRUITINGPhase 3NCT03067181

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ...

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the...

Sponsor: Children's Oncology GroupEnrolling: 178020 locations
RECRUITINGNCT06572735

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With...

Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models,...

Sponsor: Hospices Civils de LyonEnrolling: 5016 locations
RECRUITINGNCT06726642

CfDNA in Hereditary And High-risk Malignancies 2

The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new...

Sponsor: University Health Network, TorontoEnrolling: 10008 locations
RECRUITINGNCT06566716

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after...

Sponsor: Cleo Diagnostics LtdEnrolling: 10008 locations
RECRUITINGPhase 1NCT06234423

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other...

Sponsor: OnCusp Therapeutics, Inc.Enrolling: 26315 locations
RECRUITINGNCT05051722

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer)...

Sponsor: Mayo ClinicEnrolling: 311020 locations
RECRUITINGPhase 1 / Phase 2NCT05773859

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor...

Sponsor: Radboud University Medical CenterEnrolling: 101 location
RECRUITINGPhase 1NCT06515613

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific...

Sponsor: Context Therapeutics Inc.Enrolling: 15614 locations
RECRUITINGPhase 2NCT06014190

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a...

Sponsor: Hansoh BioMedical R&D CompanyEnrolling: 46020 locations
RECRUITINGNCT06855706

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage...

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity...

Sponsor: Roswell Park Cancer InstituteEnrolling: 1201 location
RECRUITINGPhase 2NCT01174121

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large...

Sponsor: National Cancer Institute (NCI)Enrolling: 3321 location
RECRUITINGNCT07289399

Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS?

Women with psoriasis usually develop many complications including polysyctic ovarian syndrome (PCOS). Nowdays, diet restriction combimed with phsyical exercises may improve both...

Sponsor: Cairo UniversityEnrolling: 401 location
RECRUITINGNCT06727487

OvS Breast: Ovarian Suppression in Breast Cancer Interventions

The goal of this clinical trial is to compare a combined intervention based on physical exercise, nutritional control, and individualized psycho-oncological support can achieve...

Sponsor: Universidad Pontificia ComillasEnrolling: 302 locations
RECRUITINGEarly Phase 1NCT06660511

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the...

Ovarian cancer is one of the three major malignant tumors of the female reproductive system. Even if newly diagnosed ovarian cancer patients undergo ideal tumor cell reduction...

Sponsor: Second Xiangya Hospital of Central South UniversityEnrolling: 51 location
RECRUITINGPhase 1 / Phase 2NCT07067255

Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer

This is a multicenter, open-label Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell...

Sponsor: Essen BiotechEnrolling: 801 location
RECRUITINGNCT02288676

DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers...

Sponsor: McGill UniversityEnrolling: 12001 location
RECRUITINGNCT07129434

Strengthening Healthy Emotional Co-regulation of Mothers With PCOS and Obesity and Their Infants

It is both timely and important to invest in interventions that can improve healthy emotional co-regulation. It is proposed to evaluate the feasibility and limited efficacy of an...

Sponsor: Oulu University HospitalEnrolling: 401 location
RECRUITINGNCT07270679

Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy...

Italian Cancer Registry data show a steady increase in the number of cancer survivors due to advances in treatment. However, these treatments can impair ovarian function, causing...

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 501 location

Showing 50 of 118 trials.Search all Ovarian Cancer trials

Frequently Asked Questions

There are currently 118 clinical trials for Ovarian Cancer, with 118 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Ovarian Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Ovarian Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.